Pink Viagra sales tank
A few weeks ago “pink Viagra”, more properly known as Addyi, got a green light from the FDA. The drug purports to treat “hypoactive sexual desire disorder” in women. The day after the approval, Sprout Pharmaceuticals, a small company with the patent, was sold for US$1 billion in cash to Valeant Pharmaceuticals International. Valeant obviously thought it had a winner.
It turns out that it has backed the wrong horse. In the first few weeks, only 227 prescriptions have been filled. “I thought there was going to be this huge onslaught,” the director of the Women’s Health Clinic at the Mayo Clinic told Bloomberg Business.
Addyi has a lot of drawbacks; it has potentially deadly side effects, women can’t drink alcohol while using it; it costs US$780 a month; and it must be taken daily. But the biggest problem might be that Valeant believed Sprout’s canny public relations campaign which promoted sex as “a basic human right” and one of the FDA’s “priority areas of unmet medical need”. Perhaps women are more interested in commitment than a Viagra they can call their own.
Michael Cook
Only 227 prescriptions have been filled.
1447673820
- How long can you put off seeing the doctor because of lockdowns? - December 3, 2021
- House of Lords debates assisted suicide—again - October 28, 2021
- Spanish government tries to restrict conscientious objection - October 28, 2021
More Stories
Mortality rates for American kids are rising for the first time in 50 years
US President Joe Biden is so concerned about the future of American children that he inserted a mandate for affordable...
Will Pope Francis be composted?
Will Pope Francis be composted instead of buried in St Peter’s Basilica in Rome with his predecessors? It’s unlikely. But...
The virtues and the vices of the outrageous
A Norwegian bioethicist, Anna Smajdor, recently set out a case for “Whole Body Gestational Donation” – using the wombs of...
More than 200 people have been treated with experimental CRISPR therapies
Scientists believe that CRISPR gene editing technologies will transform medicine. But how many people have been treated so far? According...
Asia-Pacific IVF market could reach US$46 billion by 2031
According to a market survey by Allied Market Research, IVF is booming in the Asia-Pacific region. The market size was...
Third global summit on human genome editing: Moving on after the He experiment
The much anticipated Third International Summit on Human Genome Editing was held in London earlier this month to explore the...